C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 812—Investigational Device ExemptionsSubpart B—Application and Administrative Action

21 C.F.R. § 812.20 (2026)

Application

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1995–2024 19citing cases
At a glance

Courts have cited this section in 19 opinions since 1995, 2 of them in the last five years. The most litigated part is subsection (a)(2) (1 case).

(a) Submission. (1) A sponsor shall submit an application to FDA if the sponsor intends to use a significant risk device in an investigation, intends to conduct an investigation that involves an exception from informed consent under § 50.24 of this chapter, or if FDA notifies the sponsor that an application is required for an investigation.

(2) A sponsor shall not begin an investigation for which FDA's approval of an application is required until FDA has approved the application.

(3) A sponsor shall submit a signed “Application for an Investigational Device Exemption” (IDE application), together with accompanying materials in electronic format, to one of the addresses in § 812.19, and if eCopy by registered mail or by hand. Subsequent correspondence concerning an application or a supplemental application shall be submitted in electronic format and if eCopy by registered mail or by hand.

(4)(i) A sponsor shall submit a separate IDE for any clinical investigation involving an exception from informed consent under § 50.24 of this chapter. Such a clinical investigation is not permitted to proceed without the prior written authorization of FDA. FDA shall provide a written determination 30 days after FDA receives the IDE or earlier.

(ii) If the investigation involves an exception from informed consent under § 50.24 of this chapter, the sponsor shall prominently identify on the cover sheet that the investigation is subject to the requirements in § 50.24 of this chapter.

(b) Contents. An IDE application shall include, in the following order:

(1) The name and address of the sponsor.

(2) A complete report of prior investigations of the device and an accurate summary of those sections of the investigational plan described in § 812.25(a) through (e) or, in lieu of the summary, the complete plan. The sponsor shall submit to FDA a complete investigational plan and a complete report of prior investigations of the device if no IRB has reviewed them, if FDA has found an IRB's review inadequate, or if FDA requests them.

(3) A description of the methods, facilities, and controls used for the manufacture, processing, packing, storage, and, where appropriate, installation of the device, in sufficient detail so that a person generally familiar with good manufacturing practices can make a knowledgeable judgment about the quality control used in the manufacture of the device.

(4) An example of the agreements to be entered into by all investigators to comply with investigator obligations under this part, and a list of the names and addresses of all investigators who have signed the agreement.

(5) A certification that all investigators who will participate in the investigation have signed the agreement, that the list of investigators includes all the investigators participating in the investigation, and that no investigators will be added to the investigation until they have signed the agreement.

(6) A list of the name, address, and chairperson of each IRB that has been or will be asked to review the investigation and a certification of the action concerning the investigation taken by each such IRB.

(7) The name and address of any institution at which a part of the investigation may be conducted that has not been identified in accordance with paragraph (b)(6) of this section.

(8) If the device is to be sold, the amount to be charged and an explanation of why sale does not constitute commercialization of the device.

(9) A claim for categorical exclusion under § 25.30 or § 25.34 or an environmental assessment under § 25.40.

(10) Copies of all labeling for the device.

(11) Copies of all forms and informational materials to be provided to subjects to obtain informed consent.

(12) Any other relevant information FDA requests for review of the application.

(c) Additional information. FDA may request additional information concerning an investigation or revision in the investigational plan. The sponsor may treat such a request as a disapproval of the application for purposes of requesting a hearing under part 16.

(d) Information previously submitted. Information previously submitted to the Center for Devices and Radiological Health, the Center for Biologics Evaluation and Research, or the Center for Drug Evaluation and Research, as applicable, in accordance with this chapter ordinarily need not be resubmitted, but may be incorporated by reference.

[45 FR 3751, Jan. 18, 1980, as amended at 46 FR 8956, Jan. 27, 1981; 50 FR 16669, Apr. 26, 1985; 53 FR 11252, Apr. 6, 1988; 61 FR 51530, Oct. 2, 1996; 62 FR 40600, July 29, 1997; 64 FR 10942, Mar. 8, 1999; 73 FR 49942, Aug. 25, 2008; 84 FR 68339, Dec. 16, 2019]
The 19 cases that cite 21 C.F.R. § 812.20 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENIacangelo v. Georgetown Univ., 580 F. Supp. 2d 111 (D.D.C. 2008).
cites § 812.20 13×subsections: (a)(2)cited by 15 cases
Where it cites § 812.20
“§ 360c(a) and 21 C.F.R. § 812.20 (a)(2)). See generally Plaintiffs’ Objections to Magistrate Judge Kay’s September 17, 2008 Report and Recommendation (“Pis.”
Later courts cite it for
“free-standing punitive damages claim as improperly pled” · 4 citing courts
2
GREENAda M. Martin v. Telectronics Pacing Sys., Inc., 105 F.3d 1090 (6th Cir. 1997).
cites § 812.20 4×cited by 52 cases
Where it cites § 812.20
“§ 360j(g)(3); 21 C.F.R. §§ 812.20 , 812.25, 812.27 (1996).”
The case’s holding
State products liability claims are preempted when specific federal regulations apply to the device in question, such as those governing an investigational device exemption.
Later courts cite it for
“federal requirement 'must be applicable to the device in question... and specific to a particular device.” · 3 citing courts
3
GREENMomenta Pharm., Inc. v. Teva Pharm. USA Inc., 809 F.3d 610 (Fed. Cir. 2015).
cites § 812.20 2×cited by 18 cases
Where it cites § 812.20
“” 21 C.F.R. § 812.20 (2015). In other words, quality control is “used in the manufac- ture of the device.”
Later courts cite it for
“abtox stated 'as long as an activity is reasonably related to obtaining fda approval.” · 2 citing courts
4
GREENIacangelo v. Georgetown Univ., 595 F. Supp. 2d 87 (D.D.C. 2009).
cites § 812.20 3×cited by 6 cases
Where it cites § 812.20
“(“FDCA”), and 21 C.F.R. § 812.20 , a regulation intended to implement the investigational device exemption of the FDCA) and Count IX (a negligence per se claim based on violations of 21 C.”
5
GREENUnited States v. Endotec, Inc., 563 F.3d 1187 (11th Cir. 2009).
cites § 812.20 1×cited by 15 cases
Where it cites § 812.20
“§ 360j(g) as well as 21 C.F.R. § 812.20 . The district court’s own findings of fact intimate that the Appellees manufactured and distributed the B-P Ankle device in violation of the IDE clinical study: Dr.”
Later courts cite it for
“questions of law subject to de novo review include questions of statutory and regulatory construction.” · 2 citing courts
6
GREENGuckin v. Nagle, 259 F. Supp. 2d 406 (E.D. Pa. 2003).
cites § 812.20 1×cited by 8 cases
Where it cites § 812.20
“To this end, Curon points out that the testing and investigation of a medical device for which an IDE is granted is conducted under the supervision of an IRB, which operates under the direct control of the FDA and is required by the FDA to determine whether, for example,…”
7
GREENIn re Cryomedical Sciences, Inc. Sec. Litig., 884 F. Supp. 1001 (D. Md. 1995).
cites § 812.20 1×cited by 13 cases
Where it cites § 812.20
“21 C.F.R. § 812.20 . In the absence of a determination that the device involves significant risk, however, testing can be performed at any medical institution pursuant to an “abbreviated” IDE.”
8
GREENChmielewski v. Stryker Sales Corp., 966 F. Supp. 839 (D. Minn. 1997).
cites § 812.20 1×cited by 12 cases
Where it cites § 812.20
“21 C.F.R. § 812.20 . Manufacturers must also submit a written protocol of the study’s methodology, a description of each component, and copies of all labeling and informational materials required for the patient’s consent.”
Later courts cite it for
“the fact that plaintiffs' claims are based on general common law duties does not save them from being preempted,, if a conflicting device-specific federal regulation exists.” · 1 citing court
cites § 812.20 1×cited by 11 cases
Vacated: 2 citing opinions add another limit ("vacated (caution)").
Where it cites § 812.20
“§ 360j(g)(3); 21 C.F.R. §§ 812.20 , 812.25, 812.27. The Telectronics Guardian ATP 4210 Implantable Cardioverter-Defibrillator-De-mand Pacemaker (“device”) is an investiga-tional medical device not yet approved by the FDA for general release to the marketplace.”
Later courts cite it for
“the representations that can, cannot, and must be made about an investigational device are all determined by the fda.” · 2 citing courts
10
GREENIacangelo v. Georgetown Univ., 560 F. Supp. 2d 53 (D.D.C. 2008).
cites § 812.20 1×cited by 5 cases
Where it cites § 812.20
“21 C.F.R. § 812.20 (a) ..., by using Histoacryl and its combination Lipiodol in the treatment of Karyn Kerris.”
Later courts cite it for
“exclusion of all such testimony from the expert reports would require such reports to be revised and perhaps rewritten because such legal conclusions and state of mind opinions are commingled with permissible expert medical testimony....” · 2 citing courts
11
cites § 812.20 1×cited by 2 cases
Summary
No passage or summary on file for this case yet.
12
GREENIsbell v. Medtronic, Inc., 97 F. Supp. 2d 849 (W.D. Tenn. 1998).
cites § 812.20 3×cited by 1 case
Where it cites § 812.20
“Pursuant to 21 C.F.R. § 812.20 , the manufacturer must submit an application setting forth a complete report of all prior investigations and a “description of the methods, facilities, and controls used for the manufacture, processing, packing, storage, and where appropriate,…”
13
NO FLAGRobinson v. Endovascular Tech., Inc., 190 Cal. App. 4th 1490 (Ct. App. 2010).
cites § 812.20 7×cited by 0 cases
Where it cites § 812.20
“( 21 C.F.R. §§ 812.20 , 812.42, 812.62 (1994).”
14
NO FLAGChannel MedSystems, Inc. v. Boston Sci. Corp., No. 2018-0673-AGB (Del. Ch. Dec. 18, 2019).
cites § 812.20 2×cited by 0 cases
Where it cites § 812.20
“Specifically, 21 C.F.R. § 812.20 (b)(3) provides, in relevant part, that an IDE application “shall include”: A description of the methods, facilities, and controls used for the manufacture, processing, packing, storage, and, where appropriate, installation of the device, in…”
15
NO FLAGIacangelo v. Georgetown Univ., No. 2005-2086 (D.D.C. Feb. 4, 2009).
cites § 812.20 3×cited by 0 cases
Where it cites § 812.20
“(“FDCA”), and 21 C.F.R. § 812.20 , a regulation intended to implement the investigational device exemption of the FDCA) and Count IX (a negligence per se claim based on violations of 21 C.”
16
GREENMize v. Mentor Worldwide LLC, 51 Cal. App. 5th 850 (Ct. App. 2020).
cites § 812.20 1×cited by 0 cases
Where it cites § 812.20
“(See 21 C.F.R. §§ 812.20 (b), 812.25.) The FDA must then determine that the benefits to test participants and the knowledge to be gained from the tests outweigh the device’s risks.”
17
GREENEdwards Lifesciences Corp. v. Meril Life Sciences Pvt. Ltd., No. 22-1877 (Fed. Cir. Mar. 25, 2024).
cites § 812.20 1×cited by 0 cases
Summary
No passage or summary on file for this case yet.
18
NO FLAGIACANGELO v. Georgetown Univ., 710 F. Supp. 2d 83 (D.D.C. 2010).
cites § 812.20 1×cited by 0 cases
Where it cites § 812.20
“§ 360c(a)(II) and 21 C.F.R. § 812.20 (a)(2) by obtaining and using unapproved “artificial embolization devices” without obtaining an IDE from the FDA.”
19
NO FLAGIacangelo v. Georgetown Univ., No. 2005-2086 (D.D.C. May 7, 2010).
cites § 812.20 1×cited by 0 cases
Where it cites § 812.20
“§ 360c(a)(II) and 21 C.F.R. § 812.20 (a)(2) by obtaining and using unapproved “artificial embolization devices” without obtaining an IDE from the FDA.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199520092024

One bar per year. Tallest: 3 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.6Fed. Cir.36th Cir.2Cal. Ct. App.211th Cir.1Del. Ch.1D. Md.1D. Minn.1

The 8 courts with the most citing cases, of 10 courts in all.

By subsection
(a)(2)1 case
Iacangelo v. Georgetown Univ., 580 F. Supp. 2d 111 (D.D.C. 2008).“§ 360c(a) and 21 C.F.R. § 812.20 (a)(2)). See generally Plaintiffs’ Objections to Magistrate Judge Kay’s September 17, 2008 Report and Recommendation (“Pis.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com